Literature DB >> 8742236

Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention.

E A Eaton1, U K Walle, A J Lewis, T Hudson, A A Wilson, T Walle.   

Abstract

The common dietary constituent quercetin was a potent inhibitor of sulfoconjugation of acetaminophen and minoxidil by human liver cytosol, partially purified P-form phenolsulfotransferase (PST), and recombinant P-form PST, with IC50 values of 0.025-0.095 microM. Quercetin inhibition of acetaminophen was noncompetitive with respect to acceptor substrate, with a Ki value of 0.067 microM. A number of other flavonoids, such as fisetin, galangin, myricetin, kaempferol, chrysin, and apigenin, were also potent inhibitors of P-form PST-mediated sulfation, with IC50 values < 1 microM. Studies of structural analogs indicated the flavonoid 7-hydroxyl group as particularly important for potent inhibition. Potential human metabolites of quercetin were poor inhibitors. Curcumin, genistein, and ellagic acid (other polyphenolic natural products) were also inhibitors of P-form PST, with IC50 values of 0.38-34.8 microM. Quercetin was also shown to inhibit sulfoconjugation by the human hepatoma cell line Hep G2. Although less potent in this intact cell system (IC50 2-5 microM), quercetin was still more potent than 2,6-dichloro-4-nitrophenol, the classical P-form PST inhibitor that has been shown to be an inhibitor also in vivo. These observations suggest the potential for clinically important drug interactions, as well as a possible role for flavonoids as chemopreventive agents in sulfation-induced carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8742236

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  25 in total

1.  Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers.

Authors:  Laurie P Volak; Michael J Hanley; Gina Masse; Suwagmani Hazarika; Jerold S Harmatz; Vladimir Badmaev; Muhammed Majeed; David J Greenblatt; Michael H Court
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

2.  Improving the oral bioavailability of beneficial polyphenols through designed synergies.

Authors:  Arjan Scheepens; Kee Tan; James W Paxton
Journal:  Genes Nutr       Date:  2009-10-20       Impact factor: 5.523

Review 3.  Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention.

Authors:  Xin Tong; Jill C Pelling
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

Review 4.  Which sources of flavonoids: complex diets or dietary supplements?

Authors:  Sarah Egert; Gerald Rimbach
Journal:  Adv Nutr       Date:  2011-01-10       Impact factor: 8.701

5.  Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways.

Authors:  Wen Jiang; Ming Hu
Journal:  RSC Adv       Date:  2012-09-21       Impact factor: 3.361

6.  Plant flavone apigenin: An emerging anticancer agent.

Authors:  Eswar Shankar; Aditi Goel; Karishma Gupta; Sanjay Gupta
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

7.  Pharmacogenetics of SULT1A1.

Authors:  Jaclyn Daniels; Susan Kadlubar
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

8.  Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents.

Authors:  Roberta S King; Anasuya A Ghosh; Jinfang Wu
Journal:  Curr Drug Metab       Date:  2006-10       Impact factor: 3.731

9.  Sulfation of dietary flavonoids by human sulfotransferases.

Authors:  C Huang; Y Chen; T Zhou; G Chen
Journal:  Xenobiotica       Date:  2009-04       Impact factor: 1.908

10.  Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor.

Authors:  Laurie P Volak; Senait Ghirmai; John R Cashman; Michael H Court
Journal:  Drug Metab Dispos       Date:  2008-05-14       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.